| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/15/2003 | US6548548 Cardiovascular disorders; anticholesterol agents |
| 04/15/2003 | US6548546 HIV integrase inhibitors |
| 04/15/2003 | US6548542 Vision through photodynamic therapy of the eye |
| 04/15/2003 | US6548540 Administering dithiocarbamate thiolate anions to sensitize humans to conventional chemotherapy by blocking the p-glycoprotein membrane toxin extrusion pump |
| 04/15/2003 | US6548529 Heterocyclic containing biphenyl aP2 inhibitors and method |
| 04/15/2003 | US6548527 Treatments for immune-mediated ear disorders |
| 04/15/2003 | US6548526 Isothiazole derivatives useful as anticancer agents |
| 04/15/2003 | US6548518 As well as 5-HT3 antagonists and 5-HT4 agonists; for preventing or managing gastro-esophageal reflux disease and/or emesis |
| 04/15/2003 | US6548507 Use of sodium channel antagonists in the treatment of diseases mediated or exacerbated by neuronal apoptosis, such as multiple sclerosis; administering drugs such as lamotrigine |
| 04/15/2003 | US6548501 Composition and methods for stimulating gastrointestinal motility |
| 04/15/2003 | US6548497 Methods of reducing non-inflammatory pain |
| 04/15/2003 | US6548490 Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 04/15/2003 | US6548482 Treatment of osteoporosis |
| 04/15/2003 | US6548481 A salt form of a dipeptide compound formed from an amino acid and a thiazolidine or pyrrolidine group, and the salts are selected from acetates, tartrates, fumarates, succinates, phosphates and sulfates |
| 04/15/2003 | US6548478 Virginiamycin mixture |
| 04/15/2003 | US6548476 Dimeric inhibitors of influenza neuraminidase |
| 04/15/2003 | US6548475 Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury |
| 04/15/2003 | US6548281 Polypeptides, polynucleotides formed via recombination; for screening for antibacterial compounds |
| 04/15/2003 | US6548270 An expression vector comprising a recombinant polynucleotide encoding a protein containing specific amino acid sequence; genetic engineering |
| 04/15/2003 | US6548262 Hemostasis system-related disorders treatment |
| 04/15/2003 | US6548083 Prolonged release active agent dosage form adapted for gastric retention |
| 04/15/2003 | US6548068 Genetic engineered vaccine; gene coding antigen to disease and genetic engineerded viruses inserted into genome |
| 04/15/2003 | US6548062 Preferred for the treatment of prostate or pancreatic cancer. |
| 04/15/2003 | CA2381329C Medicaments |
| 04/15/2003 | CA2261099C Antithrombotic and antiatherogenic pharmaceutical composition including a thienopyridine derivative and an hmg-coa-reductase inhibitor |
| 04/15/2003 | CA2084775C Method of treating human prostatic adenocarcinoma |
| 04/15/2003 | CA2053208C Hydroxyalkylquinoline ether acids as leukotriene antagonists |
| 04/12/2003 | CA2407214A1 Method of monitoring neuroprotective treatment |
| 04/11/2003 | WO2002032899A1 Novel anticholinergic agents that can be used as medicaments and method for the production thereof |
| 04/11/2003 | WO2002032898A2 Novel anticholinergics, method for the production thereof and use thereof as medicaments |
| 04/10/2003 | WO2003029824A1 Method and agent for diagnosing and treating chronic inflammatory bowel diseases |
| 04/10/2003 | WO2003029488A2 A method for the early detection of cancer |
| 04/10/2003 | WO2003029465A1 HepNaDC GENE |
| 04/10/2003 | WO2003029464A2 Genes associated with mast cell activation |
| 04/10/2003 | WO2003029451A2 Histone deacetylase 9 |
| 04/10/2003 | WO2003029437A2 Secreted proteins |
| 04/10/2003 | WO2003029434A2 Novel molecules of the hkid-1-related protein family and uses thereof |
| 04/10/2003 | WO2003029428A2 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
| 04/10/2003 | WO2003029418A2 Proliferation and differentiation of stem cells using extracellular matrix and other molecules |
| 04/10/2003 | WO2003029417A2 Nutrient medium for maintaining neural cells in injured nervous system |
| 04/10/2003 | WO2003029413A2 A novel g protein-coupled receptor, gave 10 |
| 04/10/2003 | WO2003029410A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 04/10/2003 | WO2003029293A2 Modulators of notch ic protease activity for use in immunotherapy |
| 04/10/2003 | WO2003029276A2 Copolymers for suppression of autoimmune diseases, and methods of use |
| 04/10/2003 | WO2003029268A1 Androstane 17-beta-carboxamides as androgen receptor modulators |
| 04/10/2003 | WO2003029264A2 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
| 04/10/2003 | WO2003029224A1 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | WO2003029216A1 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | WO2003029210A2 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 04/10/2003 | WO2003029209A2 Chemical compounds |
| 04/10/2003 | WO2003028777A1 Inhibition of exoproteins using isoprenoids |
| 04/10/2003 | WO2003028764A1 Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
| 04/10/2003 | WO2003028762A1 Novel antimicrobial resistance blocking compositions |
| 04/10/2003 | WO2003028747A1 Ingestible nerve and circulatory nutritional formulation |
| 04/10/2003 | WO2003028742A1 Strontium compound for treatment of sub-dermal soft tissue pain |
| 04/10/2003 | WO2003028740A1 Compositions for the treatment of pilosebaceous gland inflammations comprising aluminium fluoride |
| 04/10/2003 | WO2003028737A1 Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon |
| 04/10/2003 | WO2003028730A2 Pharmaceutical combinations of pde-v inhibitors and other agents |
| 04/10/2003 | WO2003028729A2 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | WO2003028726A1 Quinoline derivatives as neuropeptide y antagonists |
| 04/10/2003 | WO2003028711A2 Use of c-kit inhibitors for the treatment of myeloma |
| 04/10/2003 | WO2003028710A2 Compounds for reducing excessive intake of food |
| 04/10/2003 | WO2003028700A2 Water soluble nanoparticles of hydrophilic and hydrophobic active materials |
| 04/10/2003 | WO2003028697A2 Liposome loading with metal ions |
| 04/10/2003 | WO2003028696A2 Compositions for delivery of drug combinations |
| 04/10/2003 | WO2003028656A2 Adjuvant compositions |
| 04/10/2003 | WO2003028646A2 Methods of treating drug-resistant bacterial infections |
| 04/10/2003 | WO2003028634A2 Method of treatment using ligand-immunogen conjugates |
| 04/10/2003 | WO2003028633A2 Parenteral delivery systems |
| 04/10/2003 | WO2003028630A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 04/10/2003 | WO2003028590A1 Rational drug therapy device and methods |
| 04/10/2003 | WO2003028537A2 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer |
| 04/10/2003 | WO2003028536A2 Methods for diagnosing and treating heart disease |
| 04/10/2003 | WO2003028477A2 Method of hydration ; infusion packet system(s), support member(s), delivery system(s), and method(s) ; with business model(s) and method(s) |
| 04/10/2003 | WO2003028444A1 Nonhuman mammal model of autoimmune disease having ox40l gene transferred thereinto |
| 04/10/2003 | WO2003017935A9 Human antibodies specific for interleukin 15 (il-15) |
| 04/10/2003 | WO2003014326A3 Isolation and mobilization of stem cells expressing vegfr-1 |
| 04/10/2003 | WO2003011300B1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| 04/10/2003 | WO2003002103A3 Hydrophobic dopamine agonists administered to the dermis |
| 04/10/2003 | WO2003002092A3 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 04/10/2003 | WO2003000118A3 Method for enhancing the effectiveness of cancer therapies |
| 04/10/2003 | WO2002103971A3 Multicarrier receiver |
| 04/10/2003 | WO2002102978A3 Human growth hormone antagonists |
| 04/10/2003 | WO2002102768A3 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
| 04/10/2003 | WO2002100348A8 Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| 04/10/2003 | WO2002094830A8 Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists |
| 04/10/2003 | WO2002094203A3 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 04/10/2003 | WO2002094189A3 Compositions and methods for treating or preventing convulsions or seizures |
| 04/10/2003 | WO2002092064A3 Therapeutic method for inducing tolerance |
| 04/10/2003 | WO2002083108A3 Compositions containing cgmp pde inhibitors and local anaesthetic agents for nasal application |
| 04/10/2003 | WO2002083079A9 Aerosol compositions containing formoterol for delivery to the lungs via nebulization |
| 04/10/2003 | WO2002079748A3 Withasol and methods of use |
| 04/10/2003 | WO2002078639A3 A method of treating proliferative diseases using eg5 inhibitors |
| 04/10/2003 | WO2002076472A3 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs |
| 04/10/2003 | WO2002071827A3 Retinoid x receptor modulators |
| 04/10/2003 | WO2002070070A3 Compositions having improved bioavailability of eletriptan |
| 04/10/2003 | WO2002062383A3 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases |
| 04/10/2003 | WO2002060423A3 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists |
| 04/10/2003 | WO2002060412A3 Stabilised polymeric aerosols for pulmonary gene delivery |
| 04/10/2003 | WO2002055688A3 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms |